TrialAmerican journal of hematology2018
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.
Rita Assi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
40 papers cite it
this paperpooled ittrialcites it